175 related articles for article (PubMed ID: 15119774)
1. A novel principle of attenuation for the development of new generation live flavivirus vaccines.
Kofler RM; Heinz FX; Mandl CW
Arch Virol Suppl; 2004; (18):191-200. PubMed ID: 15119774
[TBL] [Abstract][Full Text] [Related]
2. Flavivirus immunization with capsid-deletion mutants: basics, benefits, and barriers.
Mandl CW
Viral Immunol; 2004; 17(4):461-72. PubMed ID: 15671744
[TBL] [Abstract][Full Text] [Related]
3. Replication/Assembly Defective Avian Flavivirus With Internal Deletions in the Capsid Can Be Used as an Approach for Living Attenuated Vaccine.
He Y; Wang X; Guo J; Mao L; Zhang S; Hu T; Wang M; Jia R; Zhu D; Liu M; Zhao X; Yang Q; Wu Y; Zhang S; Huang J; Mao S; Ou X; Gao Q; Sun D; Liu Y; Zhang L; Yu Y; Cheng A; Chen S
Front Immunol; 2021; 12():694959. PubMed ID: 34421904
[TBL] [Abstract][Full Text] [Related]
4. Mimicking live flavivirus immunization with a noninfectious RNA vaccine.
Kofler RM; Aberle JH; Aberle SW; Allison SL; Heinz FX; Mandl CW
Proc Natl Acad Sci U S A; 2004 Feb; 101(7):1951-6. PubMed ID: 14769933
[TBL] [Abstract][Full Text] [Related]
5. Chimeric flaviviruses: novel vaccines against dengue fever, tick-borne encephalitis, and Japanese encephalitis.
Lai CJ; Monath TP
Adv Virus Res; 2003; 61():469-509. PubMed ID: 14714441
[TBL] [Abstract][Full Text] [Related]
6. Capsid protein C of tick-borne encephalitis virus tolerates large internal deletions and is a favorable target for attenuation of virulence.
Kofler RM; Heinz FX; Mandl CW
J Virol; 2002 Apr; 76(7):3534-43. PubMed ID: 11884577
[TBL] [Abstract][Full Text] [Related]
7. Flaviviruses and flavivirus vaccines.
Heinz FX; Stiasny K
Vaccine; 2012 Jun; 30(29):4301-6. PubMed ID: 22682286
[TBL] [Abstract][Full Text] [Related]
8. Live flavivirus vaccines: reasons for caution.
Seligman SJ; Gould EA
Lancet; 2004 Jun; 363(9426):2073-5. PubMed ID: 15207960
[TBL] [Abstract][Full Text] [Related]
9. A review of successful flavivirus vaccines and the problems with those flaviviruses for which vaccines are not yet available.
Ishikawa T; Yamanaka A; Konishi E
Vaccine; 2014 Mar; 32(12):1326-37. PubMed ID: 24486372
[TBL] [Abstract][Full Text] [Related]
10. Third-generation flavivirus vaccines based on single-cycle, encapsidation-defective viruses.
Widman DG; Frolov I; Mason PW
Adv Virus Res; 2008; 72():77-126. PubMed ID: 19081489
[TBL] [Abstract][Full Text] [Related]
11. Identifying Attenuating Mutations: Tools for a New Vaccine Design against Flaviviruses.
Khou C; Pardigon N
Intervirology; 2017; 60(1-2):8-18. PubMed ID: 28869941
[TBL] [Abstract][Full Text] [Related]
12. [Flaviviruses].
Ishikawa T; Konishi E
Uirusu; 2011 Dec; 61(2):221-38. PubMed ID: 22916569
[TBL] [Abstract][Full Text] [Related]
13. Flavivirus DNA vaccines: current status and potential.
Chang GJ; Davis BS; Hunt AR; Holmes DA; Kuno G
Ann N Y Acad Sci; 2001 Dec; 951():272-85. PubMed ID: 11797784
[TBL] [Abstract][Full Text] [Related]
14. Spontaneous and engineered deletions in the 3' noncoding region of tick-borne encephalitis virus: construction of highly attenuated mutants of a flavivirus.
Mandl CW; Holzmann H; Meixner T; Rauscher S; Stadler PF; Allison SL; Heinz FX
J Virol; 1998 Mar; 72(3):2132-40. PubMed ID: 9499069
[TBL] [Abstract][Full Text] [Related]
15. MicroRNA-based control of tick-borne flavivirus neuropathogenesis: Challenges and perspectives.
Teterina NL; Maximova OA; Kenney H; Liu G; Pletnev AG
Antiviral Res; 2016 Mar; 127():57-67. PubMed ID: 26794396
[TBL] [Abstract][Full Text] [Related]
16. Spontaneous mutations restore the viability of tick-borne encephalitis virus mutants with large deletions in protein C.
Kofler RM; Leitner A; O'Riordain G; Heinz FX; Mandl CW
J Virol; 2003 Jan; 77(1):443-51. PubMed ID: 12477849
[TBL] [Abstract][Full Text] [Related]
17. Traditional and novel approaches to flavivirus vaccines.
Pugachev KV; Guirakhoo F; Trent DW; Monath TP
Int J Parasitol; 2003 May; 33(5-6):567-82. PubMed ID: 12782056
[TBL] [Abstract][Full Text] [Related]
18. Recent advances in flavivirus antiviral drug discovery and vaccine development.
Ray D; Shi PY
Recent Pat Antiinfect Drug Discov; 2006 Jan; 1(1):45-55. PubMed ID: 18221133
[TBL] [Abstract][Full Text] [Related]
19. Recombinant vector derived from live attenuated measles virus: potential for flavivirus vaccines.
Brandler S; Tangy F
Comp Immunol Microbiol Infect Dis; 2008 Mar; 31(2-3):271-91. PubMed ID: 17869338
[TBL] [Abstract][Full Text] [Related]
20. Molecular mechanisms of flavivirus membrane fusion.
Stiasny K; Fritz R; Pangerl K; Heinz FX
Amino Acids; 2011 Nov; 41(5):1159-63. PubMed ID: 19882217
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
